Overview

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin & metformin and the single tablets of linagliptin and metformin when administered singularly.

Phase:

Phase 1

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Eli Lilly and Company

Treatments:

Linagliptin
Metformin

Criteria

Inclusion criteria:

1. Healthy males or females

2. Age 18 -50 years (incl)

3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)

4. Subjects must be able to understand and comply with study requirements

Exclusion criteria:

Any deviation from healthy condition